{"analyses":[{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.8078","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.65","upperLimit":"11.10","value":"7.98"},{"groupId":"OG001","lowerLimit":"6.01","upperLimit":"10.94","value":"8.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"406"}],"units":"Participants"}],"description":"Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participant's GHS/HRQoL scale score showed a \\>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \\>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \\>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo Plus Nab-Paclitaxel"},{"description":"Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab Plus Nab-Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"The patient-reported outcome (PRO)-evaluable population is defined as patients in the ITT population with a baseline and ≥1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 58 months","title":"Time to Deterioration (TTD) in Global Health Status/Health Related Quality of Life According to European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) v3.0 in All Randomized Participants","type":"SECONDARY","unitOfMeasure":"Months"}